Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 2015 Net Sales and Adjusted EBITDA Guidance

DUBLIN, IRELAND–(Marketwired – Jul 20, 2015) – Second-quarter 2015 net sales expected to be in the range of $170 to $172 million Full-year 2015 net sales guidance range increased to $660 to $680 million Full-year 2015 adjusted EBITDA guidance range increased to $265 to $280 million Second-quarter 2015 earnings conference call scheduled for August 7, […]

Read More »

Serial Acquirer Valeant Buys Egyptian Amoun for $800 Million

Laval, Quebec-based Valeant Pharmaceuticals International, Inc. (VRX) announced today that it will acquire Mercury (Cayman) Holdings, the holding company of Amoun Pharmaceutical, for about $800 million and contingent payments. Amoun Pharmaceutical is one of the leading drug makers in Egypt. It has a large manufacturing facility in El-Oubour City, a suburb near Cairo, and five […]

Read More »

Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to Biogen Inc. This arrangement expands upon the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013. […]

Read More »

VisionGate Eyes IPO and Plans to Hire 200 New Employees

VisionGate Inc., the Phoenix-based developer of a 3D cell microscope to detect lung cancer at its earliest stages, is quietly making moves to go public. Alan Nelson, founder, chairman and CEO of VisionGate, said he’s going to need about $75 million to take the company to the next level, which includes making more fully automated […]

Read More »

Sanofi Trims Business Units From Seven to Five to Drive Growth

French drugmaker Sanofi (SNY) is streamlining its operations by reducing its number of global business units to five from seven starting in January 2016 to promote growth, the company announced this morning. Olivier Brandicourt, Sanofi’s chief executive officer, said the reorganization “is a necessary step for ensuring that Sanofi‘s new medicines and vaccines continue to […]

Read More »

Sanofi announces reorganization ahead of strategic plan

Sanofi will adopt a simplified structure centered around five global business units starting in January 2016 to promote growth, the French drugmaker said on Wednesday, as it prepares a new strategic plan to be unveiled in November. The company said the five would be: general medicines & emerging markets, specialty care, diabetes & cardiovascular, Sanofi […]

Read More »

J&J’s Nonprescription Business Could Soon Get a Lift

A Philadelphia-area Johnson & Johnson factory at the center of dozens of product recalls in recent years is getting close to reopening after a long overhaul, the company said Tuesday, a big step in J&J’s efforts to revive its non-prescription-medicines business. The Fort Washington, Pa., plant was closed in 2010 after J&J recalled more than […]

Read More »

Pfizer To Shutter Mumbai Plant

Pharma major Pfizer Ltd announced on Wednesday the shutting down of its Thane manufacturing plant from September 16 as it has become unviable, a company spokesperson said here. “The decision to close the site is based on an assessment of its long term viability and its ability to achieve the needed production. There has practically […]

Read More »

Media Agencies Battle for GlaxoSmithKline’s $1 Billion+ Business

GlaxoSmithKline has called a consolidation review for its global media assignment. The pharmaceutical giant is estimated to spend more than $1 billion annually on ads worldwide. The review will pit the client’s U.S. media shop, PHD, part of Omnicom, against WPP’s MediaCom, which handles the company’s media business in a number of regions outside the […]

Read More »

Celgene to buy Receptos for $7.2 billion; gains promising drug

Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. Celgene, whose shares rose nearly 6 percent in extended trading to $130.15, said it would pay $232 […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom